Dropout rates for intent-to-treat and per protocol analyses

American Journal of Ophthalmology

Volumn 137, Issue 4, 2004, Pages 639-645

  Stewart, William C ^a,b,d   Jackson, Angi L ^c   Jenkins, Jessica N ^a  

^a Pharmaceutical Research Network   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Charleston Research Company LLC   (United States)

^d University of South Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRIMONIDINE; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; DORZOLAMIDE; LATANOPROST; PROSTAGLANDIN; TIMOLOL; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER;

CLINICAL TRIAL; DRUG CLASSIFICATION; DRUG SCREENING; GLAUCOMA; HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SAMPLE SIZE; STATISTICAL SIGNIFICANCE;

EID: 1842504326     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(03)01437-5     Document Type: Review

References (37)

1. Camras C.B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 103:1996;138-147.
2. Stewart W.C., Cohen J.S., Netland P.A., Weiss H., Nussbaum L.L. Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group. Am J Ophthalmol. 124:1997;498-505.
3. Katz L.J. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 11:2002;119-126.
4. Katz L.J. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol. 127:1999;20-26.
5. Serle J.B. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv Ophthalmol. 41:(Suppl 1):1996;39-47.
6. LeBlanc R.P. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology. 105:1998;1960-1967.
7. Javitt J.C., Schiffman R.M. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension a randomized clinical trial. Brimonidine Outcomes Study Group I. J Glaucoma. 9:2000;224-234.
8. Shedden A., Laurence J., Tipping R., the Timoptic-XE 0.5% Study Group. Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension a six-month, double-masked, multicenter study. Clin Ther. 23:2001;440-450.
9. Stewart W.C., Cohen J.S., Netland P.A., Weiss H., Nussbaum L.L. Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group. Am J Ophthalmol. 124:1997;498-505.
10. Stewart W.C., Dubiner H.B., Mundorf T.K., et al. Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. Am J Ophthalmol. 127:1999;142-147.
11. Silver L.H. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol. 126:1998;400-408.
12. Boyle J.E., Ghosh K., Gieser D.K., Adamsons I.A. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology. 105:1998;1945-1951.
13. Clineschmidt C.M., Williams R.D., Snyder E., Adamsons I.A. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology. 105:1998;1952-1959.
14. March W.F., Ochsner K.I. The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. Am J Ophthalmol. 129:2000;136-143.
15. Michaud J.E., Friren B., the International Brinzolamide Adjunctive Study Group. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 132:2001;235-243.
16. Camras C.B., Wax M.B., Ritch R., et al. Latanoprost treatment for glaucoma effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group. Am J Ophthalmol. 126:1998;390-399.
17. Bucci M.G. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group. J Glaucoma. 8:1999;24-30.
18. Emmerich K.H. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension. A 3-month randomised study. Graefes Arch Clin Exp Ophthalmol. 238:2000;19-23.
19. Susanna R. Jr, Giampani J. Jr, Borges A.S., Vessani R.M., Jordao M.L. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology. 108:2001;259-263.
20. Lass J.H., Eriksson G.L., Osterling L., Simpson C.V., the Latanoprost Corneal Effects Study Group. Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol a double-masked, randomized, one-year study. Ophthalmology. 108:2001;264-271.
21. O'Donoghue E.P. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension a 3 month, randomised study. Ireland Latanoprost Study Group. Br J Ophthalmol. 84:2000;579-582.
22. Laibovitz R.A., VanDenburgh A.M., Felix C., et al. Comparison of the ocular hypotensive lipid AGN 192024 with timolol dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol. 119:2001;994-1000.
23. Petounis A., Mylopoulos N., Kandarakis A., Andreanos D., Dimitrakoulias N. Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension a randomized, open-label, multicenter study in Greece. J Glaucoma. 10:2001;316-324.
24. Netland P.A., Landry T., Sullivan E.K., et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 132:2001;472-484.
25. Goldberg I., Cunha-Vaz J., Jakobsen J.E., et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 10:2001;414-422.
26. Nordmann J.P., Mertz B., Yannoulis N.C., et al. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. Am J Ophthalmol. 133:2002;1-10.
27. Kampik A., Arias-Puente A., O'Brart D.P., Vuori M.L., the European Latanoprost Study Group. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension a randomized observer-masked multicenter study. J Glaucoma. 11:2002;90-96.
28. Fellman R.L., Sullivan E.K., Ratliff M., et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure a 6-month, masked, multicenter trial. Ophthalmology. 109:2002;998-1008.
29. Higginbotham E.J., Feldman R., Stiles M., Dubiner H., the Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy one-year randomized trial. Arch Ophthalmol. 120:2002;915-922.
30. Higginbotham E.J., Schuman J.S., Goldberg I., et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 120:2002;1286-1293.
31. Jampel H.D., Bacharach J., Sheu W.P., et al. Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure. Am J Ophthalmol. 134:2002;863-871.
32. Noecker R.S., Dirks M.S., Choplin N.T., et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 135:2003;55-63.
33. Watson P., Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 103:1996;126-137.
34. Camras C.B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 103:1996;138-147.
35. Mishima H.K., Masuda K., Kitazawa Y., Azuma I., Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol. 114:1996;929-932.
36. Walker G.A. Considerations in the development of statistical analysis plan for clinical studies. 1999;Collins-Wellesly, San Diego.
37. Department of Health and Human Service. Food and Drug Administration (Docket No. 97D-0174), international conference on harmonisation guidance on statistical principles for clinical trials. Federal Register. 63:1998;49583-49598.